EP. 1: FDA Pushes Zenocutuzumab Decision Date in NGR1+ NSCLC, PDAC
The FDA has extended its review of zenocutuzumab's in NRG1+ NSCLC and PDAC to February 2025, with efficacy and safety data from the eNRGy trial supporting the application.
